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AAA protein(IBM) associated with Paget disease of the bone (PDB) and frontotemporal
dementia (FTD) (now called IBMPFD), is a progressive autosomal dominant disorder that was recently
identiﬁed as being caused by mutations in the VCP (p97 or CDC48) gene which plays a key role in the
ubiquitin–proteasome dependent degradation of cytosolic proteins and in the retro translocation of
misfolded proteins from the endoplasmic reticulum into the cytoplasm. Approximately 90% of the affected
persons in the study have myopathy or muscle weakness particularly of the shoulder and hip girdles, which
can lead to loss of walking ability and even death by complications of respiratory and cardiac failure. About
half of affected study participants have Paget disease of bone characterized by abnormal rates of bone growth
that can result in bone pain, enlargement and fractures. Findings of premature FTD affecting behavior and
personality are seen in a third of affected individuals. Within 20 IBMPFD families whose data was analyzed
for this study, ten missense mutations have been identiﬁed, the majority of which are located in the N-
terminal ubiquitin binding domain. Inclusions seen in the muscle, brain and heart in VCP disease contain
ubiquitin, beta amyloid and TDP-43, also seen in other neurodegenerative disorders thus implicating
common pathways in their pathogenesis.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The inclusion body myopathies encompass a heterogeneous group
of autosomal recessive and autosomal dominant disorders which
include sporadic inclusion body myositis (s-IBM) and hereditary
inclusion body myopathies (h-IBM). Both autosomal dominant (IBM1)
and autosomal recessive hereditary inclusion body myopathies have
been previously studied. The autosomal recessive form, IBM2, was ﬁrst
identiﬁed in a Persian Jewish family as affecting the leg muscles but
sparing the quadriceps. Subsequent studies mapped this form of HIBM
to 9p13-12 and identiﬁedmutations in the UDP-N-acetylglucosamine-
2-epimerase/N-acetylmannosamine kinase (GNE) gene as causal [1].
Nonaka myopathy or distal myopathy with rimmed vacuoles (OMIM
605820) is allelic to IBM2 [2]. Autosomal dominant type of IBM— type
3 associated with congenital joint contractures, external ophthalmo-
plegia, and proximal muscle weakness maps to chromosome region
17p13.1 and is associated with mutations in myosin heavy chain
MYHC2A, the major isoform in type 2A ﬁbers. Inclusion body
myopathy with Paget disease of bone and frontotemporal dementia
(IBMPFD, OMIM 167320) is a highly penetrant, autosomal dominant1 714 456 5610.
ll rights reserved.progressive disorder that maps to chromosome 9p21-p12 [3].
Although the concurrent presentation of Paget's disease, neuronal
degeneration, and myopathy has been documented previously [4–6],
this combination was recognized as a genetically distinct clinical
syndrome only in 2000 [7]. A diagnosis of IBMPFD should be
considered if an individual who has two or more of the following
features: progressive myopathy, Paget disease of bone, and Fronto-
temporal dementia. Tau mutations were ﬁrst identiﬁed in several
families with autosomal dominant hereditary frontotemporal demen-
tia (FTD) and Parkinsonism linked to chromosome 17 (FTDP-17) [8].
The majority of FTD families however have no demonstrable tau
mutations [9], however recently have been identiﬁed with mutations
in the progranulin gene [10,11]. IBMPFD was subsequently attributed
to being caused by mutations in the gene encoding Valosin-Contain-
ing Protein (VCP), a member of the AAA-ATPase superfamily and an
essential component of the ubiquitin–proteasome pathway-mediated
Endoplasmic Reticulum-Associated Degradation (ERAD) [12]. Our
study has expanded to include patients from the original 13 North
American families reported by Watts et. al (2004) [12], families
reported from Germany [13], France [14], Austria [15] and additional
families studied by our group [16], altogether harboring ten VCP
missense mutations, approximately half of which represent mutation
hot spots.
Fig. 1. Phenotypes associated with VCP disease. Reprinted from the Inclusion Body
Myopathy Associated with Paget Disease of Bone and/or Frontotemporal Dementia
GeneReview with permission from GeneTests (www.genetests.org) and University of
Washington, Seattle.
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2.1. Myopathy
Among these unrelated families, 122 individuals presented clini-
cally with a combination of components of the familial disease: 107
(87.7%) had myopathic weakness at a mean age of 42.9 (range 3–66 y).
The myopathy is characterized by adult-onset, slowly progressive
distal and proximal muscle weakness with initial involvement of the
hip girdle and shoulder girdle muscle groups. Patients exhibit
abnormal, waddling gait; inability to raise the arms; difﬁculty in
climbing stairs; and mild weakness of the hands. Clinical features
include a generalized reduction or absence of tendon reﬂexes, normal
nerve conduction, and myopathic electromyogram (EMG). The serum
creatine phosphokinase (CPK) levels are typically normal to slightly
elevated (mean 195U/L, range 40–1145U/L; normal range 20–222U/L)
with the highest levels having been identiﬁed in the early stages of the
disease. Light microscopy of muscle biopsy reveals nonspeciﬁc
changes: variability in ﬁber size, type I ﬁber predominance, and
atrophic and hypertrophic ﬁbers. Fibersmay contain single ormultiple
rimmed vacuoles and cytoplasmic VCP- and ubiquitin-positive inclu-
sions visible in some ﬁbers are characteristic of inclusion body
myopathy. The inclusions appear with time and can be observed at a
later stage of the disease in some individuals. In advanced cases, severe
degenerative muscle changes and fatty replacement of muscle ﬁbers
may be noted. Unlike sIBM inﬂammatory cells are notably absent.
Affected patients lose ambulation, become bedridden, and develop
quadriparesis, with respiratory and cardiac failure eventually leading
to death between the ages of 40s–60s. Historically, patients suffering
from the debilitating effects of this ultimately lethal disease have been
misdiagnosed with a range of diseases including Limb–Girdle
Muscular Dystrophy (LGMD), Amyotrophic Lateral Sclerosis (ALS),
muscular dystrophy, facioscapulohumeral muscular dystrophy (FSH),
scapuloperoneal muscular dystrophy, and myotonic dystrophy [7].
Immunohistochemical analysis with a polyclonal antibody to VCP
indicates the localization of VCP to rounded aggregates present
sporadically in both normal and aberrant muscle ﬁbers [12]. Atrophic
and vacuolatedmuscle ﬁbers containing abundant cytoplasmic-paired
helical ﬁlaments with epitopes of phosphorylated tau, congophilia,
abnormal accumulation of beta amyloid precursor protein (APP)
epitopes, and accumulation of apolipoprotein E (ApoE) were observed
in one family [17]. Weihl et al. [18] evaluated the immunolocalization
of FTD-U associated proteins, VCP and TDP-43 (TAR DNA binding
protein 43) in muscle because of the ﬁndings of TDP-43 positive
inclusions in the brains of affected individuals by Neumann et al. [19].
Both proteins are normally present in myonuclei and accumulate as
sarcoplasmic inclusions, which in some cases co-localize with
ubiquitin in sIBM and IBMPFD.
2.2. Paget's disease of bone
Paget's disease of the bone (PDB) was identiﬁed in 56 individuals
(45.9%) at a mean age of 41.7 years (range 23–65 y) versusN50 years. in
the general population. The typical distribution of Paget's disease
includes the spine, pelvis, scapulae and skull. PDB is often asympto-
matic; however, patients may exhibit spine or hip pain, skeletal
deformity and localized enlargement. Additionally the skin may feel
warm to the touch because of increased vascularity. A clinical
diagnosis of Paget's disease should be conﬁrmed through radiology,
radionuclide bone scanning, and biochemical testing of bone resorp-
tion or formation parameters. Radiologic surveys reveal coarse
trabeculation, cortical thickening, transverse lucent areas, and spotty
sclerosis; however, radionuclide scans provide the most sensitive
detection of abnormal bone metabolism [20]. Additional disease
manifestations include reduced height, pathologic fractures, long
bone or cranial bone deformity, or hearing loss due to eighth nervecompression by calvarial bony overgrowth. PDB is characterized by the
overactivity of abnormally large, multinucleated osteoclasts which
histologically reveal nuclear ﬁlamentous inclusions of 15 to 18 nm
paired helical ﬁlaments similar to that seen in IBM.
Serum alkaline phosphatase (ALP) concentrations were elevated in
all affected individuals with PDB (mean 359 U/L, range 58–1724 U/L;
normal range 30–130); urine pydridinoline (PYD) (mean 153, normal
31.1 IU/I); and deoxypyridinoline (DPD) concentration was increased
(mean 40 IU/L, normal 6.8 IU/L) in all affected individuals.
2.3. Frontotemporal dementia
Frontotemporal dementia (FTD) was seen only in 14 of 20 families
including46 (37.7%) patientswith ameanage ofdiagnosis of 55.1 (range
39–60) years (Fig. 1).
Early-onset frontotemporal dementia impairs executive or other
frontal lobe functions, dominated by behavioral changes. Diagnosis is
based upon drastic personality alteration including changes in affect,
decline in social interpersonal conduct, perseveration, aphasia and
emotional blunting detected by comprehensive neuropsychological
assessment. In families studied thus far, approximately 30% of affected
individuals had frontotemporal dementia with a mean age of
diagnosis of 55 years (range: 42–62 years). Several individuals were
in advanced stages of dementia when diagnosed with IBMPFD. The
relative sparing of visuospatial abilities and memory are discrimina-
tors between FTD, Alzheimer's, and other dementias. FTD is further
distinguished by cerebral atrophy in the frontal and anterior temporal
lobes of the brain rather than the hippocampal, posterior temporal
and parietal effects of Alzheimer's disease. Neuroﬁbrillary tangles,
senile plaques and Lewy bodies associated with various dementias are
also absent. Diagnosis is complicated by the inconclusive results of
structural and functional neuroimaging, including the differential
presence of focal prefrontal or anterior temporal atrophy on magnetic
resonance imaging (MRI) or computed tomography (CT).
Modiﬁer genes were evaluated because of the variable phenotype
in IBMPFD. From a database of 231 members of 15 original families,
174 had APOE genotype available for regression analysis. Data analysis
suggested a potential link between APOE4 genotype and the
frontotemporal dementia found in IBMPFD but no association was
found with the myopathy and PDB. We also observed no association
between frontotemporal dementia and microtubule associated pro-
tein tau (MAPT) H2 haplotype (p=0.5) [21].
Because of limited information on the neuropathology in IBMPFD,
we performed a systematic analysis of the brain neuropathologic
changes in eight patients with VCP mutations. A novel pattern of
ubiquitinpathologywas identiﬁed, characterized byubiquitin-positive
neuronal intranuclear inclusions and dystrophic neurites. The ubiqui-
tin pathology was abundant in the neocortex, less robust in limbic and
subcortical nuclei, and absent in the dentate gyrus. Only rare inclusions
were detected with antibodies to VCP and there was no biochemical
alteration in the VCP protein [22]. We studied the pathological
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striated muscle. IBMPFD skeletal muscle pathology is characterized
by degenerative changes and ﬁlamentous VCP- and ubiquitin-positive
cytoplasmic and nuclear protein aggregates [7,23]. The CNS pathology
is characterized by a novel pattern of ubiquitin pathology distinct from
without VCP mutations. TDP-43 was recently identiﬁed as a major
disease protein in the ubiquitin-positive inclusions of sporadic and
familial frontotemporal lobar degeneration with ubiquitin-positive
inclusions (FTLD-U). Accumulations of TDP-43 co localized with
ubiquitin pathology in IBMPFD, including both intranuclear inclusions
and dystrophic neurites [19]. These studies further support the
hypothesis that the pathogenesis of IBM and neurodegenerative
disorders, especially FTD-Us are similar.
3. Valosin-containing protein
Valosin containing protein (VCP) or p97 is a member of the AAA
protein superfamily (ATPases Associated with a variety of cellular
Activities). Typical of type II family members, VCP is characterized by
the presence of two conserved energy-generating ATPase domains
(D1 and D2), as well as a cofactor and polyubiquitin binding CDC48 N-
domain, a ﬂexible N-D1 linker, D1-D2 linker, and C-terminal domains.
VCP forms a hexameric barrel of six-fold symmetry, wherein the D1
and D2 domains of each subunit are joined in a head to tail fashion
[24] while the N-domain juts out from the apex of the D1 and D2
domains at 30° [25]. The N-terminal CDC48 domain in which the
majority of observed mutations are found is involved in ubiquitin
binding. Exons 3, 5, and 6 encode regions of the CDC48, Linker 1, and
D1 AAA-ATPase domains, wherein all but one of the identiﬁed IBMPFD
mutations have been located (Table 1).
Protein degradation in eukaryotes usually requires multiubiquity-
lation and subsequent delivery of the tagged substrates to the
proteasome [26]. Recent studies suggest the involvement of the AAA
ATPase CDC48, its cofactors, and other ubiquitin binding factors in
protein degradation, but how these proteins work together is unclear
although it has been shown that these factors cooperate sequentially
through protein–protein interactions and thereby escort ubiquitin–
protein conjugates to the proteasome. Central to this pathway is the
chaperone CDC48/p97, which coordinates substrate recruitment, E4-
catalyzed multiubiquitin chain assembly, and proteasomal targeting
[27,28]. Concomitantly, CDC48 prevents the formation of excessive
multiubiquitin chain sizes that are surplus to requirements for
degradation. In yeast, this escort pathway guides a transcription
factor from its activation in the cytosol to its ﬁnal degradation and also
mediates proteolysis at the endoplasmic reticulum by the ERAD
pathway.Table 1
List of mutations identiﬁed in VCP
Amino
acid
Base change
(ORF)
Exon Domain Exon
bp
Number of
families
References
1 R93C 277CNT 3 CDC48 148 4 [12,38,39]
2 R95G 283CNG 3 CDC48 154 2 [10]
3 R95C 283CNT 3 CDC48 154 1 P/C
4 R155C 463CNT 5 CDC48 18 5 [10,11,12,39,40]
5 R155H 464GNA 5 CDC48 19 8 [10,39,41]
6 R155P 464GNC 5 CDC48 19 1 [10]
7 R159H 476GNA 5 CDC48 31 2 [13]
8 R159C 476GNA 5 CDC48 31 2 [37,42]
9 R191Q 572GNA 5 Linker 1 127 1 [10,42]
10 L198W 593TNG 6 Linker 1 17 1 [14]
11 A232E 695CNA 6 Junction
(L1–D1)
119 1 [10]
12 T262A N/A 7 AAA D1 103 1 [42]
13 N387H 1159ANC 10 AAA D1 78 1 [14]
N/A=not available. P/C=Personal communication Joline Dalton and John Day, Dept of
Neurology, University of Minnesota, Minneapolis, MN.Numerous seemingly unrelated functions have been attributed to
this ubiquitous protein constituting 1% of the cytosol in yeast,
including ubiquitin/proteasome-dependent proteolysis through asso-
ciation with cofactor Ufd1-Npl4, cell cycle control, membrane fusion,
nuclear envelope reformation, suppression of apoptosis, regulation of
the NF-κB pathway and DNA damage response [29,30]. Studies
implicating VCP in endoplasmic reticulum-associated degradation
have shown that its malfunction results in vacuole and inclusion body
formation [29]. A recent study of VCP's speciﬁc functionality within
this pathway highlights the retention of normal ATPase activity and
hexameric structure despite the presence of the common R155H
mutation in the enzyme's N-domain [31]. Size exclusion analysis and
electron microscopy of the mutant protein proved identical to
hexameric wild-type VCP [32]. However, transfection of C2C12 cells
with R155H and R95G mutants increased the presence of ubiquitin-
conjugated proteins relative to cells both transfected with the wild-
type protein and untransfected cells. More signiﬁcantly, impairment
of the degradation of F508 mutant cystic ﬁbrosis transmembrane
regulator (F508-CFTR), a known ERAD substrate, directly implicates
perturbation of the ERAD pathway. IBMPFD thereby joins familial
forms of Alzheimer's disease, Parkinson's disease, Marinesco–Sjögren
Syndrome, and other neurodegenerative diseases in which intracel-
lular protein accumulation results from perturbation of ER chaperone
function. Each of these disorders affects genes (VCP, UBB+1, parkin,
and SYL1, respectively), which are essential in the ubiquitin–protea-
some and ER-associated degradation (ERAD) pathways. It has also
been proposed that VCP functions as a mediator for both aggregate
formation and clearance, depending on the concentration of soluble
aggregate-prone proteins, indicating that VCP has dual functions as an
aggregate formase and an unfoldase. All IBMPFD VCPs showed
elevated aggregate formase activities on both polyglutamine and
proteasome inhibitor-mediated aggregates. Biochemically, all IBMPFD
VCPs showed elevated ATPase activities as well as elevated binding
afﬁnities not only for several VCP cofactors, but also for ubiquitinated
proteins [33].
Unique to IBMPFD is the phenotypic overlap of three distinct
diseases, which can be attributed individually to gene mutations
similarly compromising ubiquitin-binding or targeting similar cellular
pathways or proteins. For example, mutations affecting the ubiquitin-
binding domain of SQSTM1/p62 are a common cause of familial and
sporadic Paget's disease of bone [34]. The ability of p62 to bind
noncovalently to ubiquitin as well as to signaling proteins suggests
that p62 may play a regulatory role that is connected to the ubiquitin
system. Similar to VCP, p62 has been shown to co-localize with
neuronal and glial ubquitin-containing inclusions in Alzheimer's
disease, Pick's disease, dementia with Lewy bodies, Parkinson's
disease, and multiple system atrophy [35]. It is notable that p97/VCP
has been shown to target IκBα for ubiquitination and degradation by
the proteasome. The degradation of IκBα results in the translocation
of NFκB from the cytoplasm to the nucleus where it activates the
expression of speciﬁc cellular genes. PDB2 is caused by exon 1
mutations in the TNFRSF11A gene on chromosome 18q22.1, which
encodes the Receptor Activator of NFκB (RANK), which is essential for
osteoclast formation [36,37].
Several novel VCP mutations have been described (Table 1) in
families and individuals with sporadically occurring disease
[13,16,38,39]. Bersano et al. [38] reported a 69 year old male with
the R159C mutation who had progressive muscle weakness since the
age of 50 years, and FTD 18 years later.We have recently identiﬁed this
mutation in a family with inclusion body myopathy, PDB, dementia
and Parkinson's disease (unpublished). Other phenotypes associated
with VCPmutations include cardiomyopathy [7,13], cataracts and liver
disease in one family, the latter consisting of elevated liver enzymes,
cholestasis, steatosis, and liver ﬁbrosis [14]. Spina et al. [42] reported
three new families with IBMPFD associated with VCP mutations. One
family had the R159C and another the R191Q mutation both of whom
747V.E. Kimonis et al. / Biochimica et Biophysica Acta 1782 (2008) 744–748had several individuals with Parkinson's disease A novel T262A
mutationwas found in a family of eight individuals with combinations
of FTD, myopathy, Paget's disease, and primary progressive aphasia in
one individual. We predict that more patients with VCP disease, both
familial and simplex will be identiﬁed with better availability of
testing (www.geneclinics.org) and wider appreciation of the variable
clinical phenotype. Genotype–phenotype correlations have been
performed in our families and it is difﬁcult to make any speciﬁc
conclusions because of the enormous intrafamilial variations seen.
The majority of the mutations are localized in the ubiquitin–
proteasome domain and it can be predicted that increased severity
would be noted amongst individuals with mutations in the ATPase
domain. Indeedwe reported amore severe phenotypewith the A232E
mutation in one family and other families are relatively small for any
conclusions to be reached.
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